294 related articles for article (PubMed ID: 24055890)
1. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z
Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890
[TBL] [Abstract][Full Text] [Related]
2. Genotoxic effect of doxorubicin-transferrin conjugate on human leukemia cells.
Szwed M; Jozwiak Z
Mutat Res Genet Toxicol Environ Mutagen; 2014 Sep; 771():53-63. PubMed ID: 25308442
[TBL] [Abstract][Full Text] [Related]
3. Changes in the activity of antioxidant barrier after treatment of K562 and CCRF-CEM cell lines with doxorubicin-transferrin conjugate.
Szwed M; Kania KD; Jozwiak Z
Biochimie; 2014 Dec; 107 Pt B():358-66. PubMed ID: 25312849
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation.
Szwed M; Laroche-Clary A; Robert J; Jozwiak Z
Cell Oncol (Dordr); 2016 Apr; 39(2):107-18. PubMed ID: 26611752
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by doxorubicin-transferrin conjugate compared to free doxorubicin in the human leukemia cell lines.
Szwed M; Laroche-Clary A; Robert J; Jozwiak Z
Chem Biol Interact; 2014 Sep; 220():140-8. PubMed ID: 24998637
[TBL] [Abstract][Full Text] [Related]
6. Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.
Szwed M; Kania KD; Jozwiak Z
Cell Oncol (Dordr); 2014 Dec; 37(6):421-8. PubMed ID: 25410120
[TBL] [Abstract][Full Text] [Related]
7. Molecular damage caused by generation of reactive oxygen species in the redox cycle of doxorubicin-transferrin conjugate in human leukemia cell lines.
Szwed M; Kania KD; Jozwiak Z
Leuk Lymphoma; 2015 May; 56(5):1475-83. PubMed ID: 25166006
[TBL] [Abstract][Full Text] [Related]
8. Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/β-catenin pathway in human leukemia cells.
Szwed M; Kania KD; Jozwiak Z
Leuk Res; 2015 Oct; 39(10):1096-102. PubMed ID: 26271413
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate.
Lemieux P; Pagé M
Anticancer Res; 1994; 14(2A):397-403. PubMed ID: 8017839
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells.
Łubgan D; Jóźwiak Z; Grabenbauer GG; Distel LV
Cell Mol Biol Lett; 2009; 14(1):113-27. PubMed ID: 18850074
[TBL] [Abstract][Full Text] [Related]
11. Assessment of pro-apoptotic activity of doxorubicin-transferrin conjugate in cells derived from human solid tumors.
Szwed M; Kania KD; Jozwiak Z
Int J Biochem Cell Biol; 2016 Jan; 70():57-67. PubMed ID: 26520467
[TBL] [Abstract][Full Text] [Related]
12. Transferrin-Bound Doxorubicin Enhances Apoptosis and DNA Damage through the Generation of Pro-Inflammatory Responses in Human Leukemia Cells.
Jedrzejczyk M; Wisniewska K; Kania KD; Marczak A; Szwed M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321722
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen.
Wang HW; Ma KL; Liu H; Zhou JY
Aging (Albany NY); 2020 Apr; 12(7):6018-6029. PubMed ID: 32259795
[TBL] [Abstract][Full Text] [Related]
14. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
Zheng Z; Aojula H; Clarke D
J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
[TBL] [Abstract][Full Text] [Related]
15. Structure-dependent antitumor activities of novel anthracyclines YM1, YM3, YM4 and YM6: drug transport properties and effects on biomacromolecule synthesis in drug sensitive and resistant leukemia cells.
Jiang XR; Macey MG; Kelsey SM; Collins PW; Gutteridge CN; Miki T; Adachi K; Yamabe S; Newland AC
J Chemother; 1993 Oct; 5(5):334-43. PubMed ID: 7508975
[TBL] [Abstract][Full Text] [Related]
16. Transferrin directed delivery of adriamycin to human cells.
Singh M; Atwal H; Micetich R
Anticancer Res; 1998; 18(3A):1423-7. PubMed ID: 9673350
[TBL] [Abstract][Full Text] [Related]
17. Can cytotoxic activity of anthracyclines be related to DNA damage?
Nishiyama M; Horichi N; Mazouzi Z; Bungo M; Saijo N; Tapiero H
Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
[TBL] [Abstract][Full Text] [Related]
18. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
[TBL] [Abstract][Full Text] [Related]
19. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells.
Berczi A; Barabas K; Sizensky JA; Faulk WP
Arch Biochem Biophys; 1993 Jan; 300(1):356-63. PubMed ID: 8424669
[TBL] [Abstract][Full Text] [Related]
20. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.
Li S; Zhao H; Mao X; Fan Y; Liang X; Wang R; Xiao L; Wang J; Liu Q; Zhao G
Pharm Res; 2019 Oct; 36(12):168. PubMed ID: 31654226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
